Cogent Biosciences, Inc. (COGT) fair value analysis
Nasdaq · Updated 2026-10-19
COGT price how computed
Valuation status
No fair-value estimate yetCOGT has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for COGT yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $29.52
- Sector
- Healthcare
- 12-month range
- $14.13–$42.84
- Market cap
- $5.12B
- From 52-week high
- -31.1%
- Shares outstanding
- 174M
- Rank in Healthcare by quality score
- #284 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for blood cancers and solid tumors, with particular emphasis on kinase inhibitor programs. The company is based in the United States and conducts its operations across research and development facilities supporting its clinical pipeline programs.
COGT currently ranks #284 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $5.12B
- P/E (trailing)
- n/m
- EPS (TTM)
- $-2.11
- Debt / equity
- 0.46
- Shares outstanding
- 174M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 38 · neutral
- 50-day average
- $33.84
- 200-day average
- $35.91
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-06
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.5%)
2026-03 ▼ miss (-5.7%)
2025-12 ▼ miss (-9.8%)
2025-09 ▲ beat (+3.8%)
2025-06 ▲ beat (+8.6%)
2025-03 ▲ beat (+9.0%)
2024-12 ▲ beat (+84.5%)
2024-09 ▼ miss (-12.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 11 buy · 1 hold · 0 sell (12 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $55.8
- Target vs last price
- +89.0%
What our data shows for COGT
- Shares are trading in the middle of their 12-month price range of $14.13–$42.84.
- The 14-day relative strength index sits at a neutral 38.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- COGT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the COGT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for COGT showed a shift this week, with the 50/200-day trend state moving from mixed to downtrend. The stock's current valuation verdict remains awaiting full valuation. This change suggests a weakening of the intermediate-term price momentum relative to the longer-term trend for the healthcare sector company.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is COGT stock undervalued?
TickrTrends has no fair-value estimate for COGT yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is COGT's TickrTrends verdict?
COGT is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does COGT compare to other Healthcare stocks?
COGT ranks #284 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is COGT overbought or oversold?
COGT's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does COGT report earnings next?
COGT's next earnings report is scheduled for 2026-11-06, per the published earnings calendar.
Does COGT usually beat earnings estimates?
Over its last 8 reported quarters COGT beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about COGT?
Of 12 analysts covering COGT, 11 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $55.8 (+89.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.